Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Vaccines
Study findings on tuberculosis vaccines are outlined in reports from C. Palma and colleagues
September 17th, 2008
Researchers detail in 'The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response,' new data in tuberculosis. "T helper type-1 response is essential to control Mycobacterium tuberculosis (MTB) infection but excessive antigen-mediated inflammation concurs to pathology. In mice challenged with MTB, the protection elicited by an Ag85B-encoding DNA vaccine, was lost when mice were boosted with Ag85B-protein in the absence of adjuvant," researchers in Rome, Italy report. "This effect was due to the expansion of a set of IFN-gamma secreting-CD4+ T cells...
Source: Vaccine Weekly (2008-09-17)
|
